Christopher Holland - Electromed Chief Officer
| ELMD Stock | USD 28.18 0.42 1.47% |
Insider
Christopher Holland is Chief Officer of Electromed
| Age | 55 |
| Address | 500 Sixth Avenue NW, New Prague, MN, United States, 56071 |
| Phone | 952 758 9299 |
| Web | https://smartvest.com |
Christopher Holland Latest Insider Activity
Tracking and analyzing the buying and selling activities of Christopher Holland against Electromed stock is an integral part of due diligence when investing in Electromed. Christopher Holland insider activity provides valuable insight into whether Electromed is net buyers or sellers over its current business cycle. Note, Electromed insiders must abide by specific rules, including filing SEC forms every time they buy or sell Electromed'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Christopher Holland over a month ago Disposition of 3600 shares by Christopher Holland of Jabil Circuit at 125.226 subject to Rule 16b-3 |
Electromed Management Efficiency
The company has return on total asset (ROA) of 0.0839 % which means that it generated a profit of $0.0839 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1253 %, meaning that it created $0.1253 on every $100 dollars invested by stockholders. Electromed's management efficiency ratios could be used to measure how well Electromed manages its routine affairs as well as how well it operates its assets and liabilities. At present, Electromed's Return On Assets are projected to increase slightly based on the last few years of reporting. At present, Electromed's Return On Assets are projected to increase slightly based on the last few years of reporting.Similar Executives
| Showing other executives | INSIDER Age | ||
| Erik Mickelson | Paragon 28 | 42 | |
| Alex Shvartsburg | LivaNova PLC | 54 | |
| Paul Badawi | Sight Sciences | 49 | |
| Lindsey Little | LivaNova PLC | N/A | |
| Daniel Bevevino | Artivion | 61 | |
| Gregory Davault | Axogen Inc | 56 | |
| Derrick Sung | Pulmonx Corp | 51 | |
| Geoffrey Rose | Pulmonx Corp | 50 | |
| Marshall Stanton | Artivion | 64 | |
| Thomas Ackerman | Artivion | 66 | |
| Lisa Paul | Pulmonx Corp | 60 | |
| BA Chemistry | Orthofix Medical | 63 | |
| Jean Holloway | Artivion | 63 | |
| Martha Morrell | Neuropace | 67 | |
| B Johnson | Paragon 28 | 68 | |
| Shanna Cottiosmanski | CONMED | 47 | |
| Michael Favet | Neuropace | 54 | |
| Dennis Maier | Artivion | 50 | |
| Jesse Selnick | Sight Sciences | N/A | |
| Krissy Wright | Paragon 28 | N/A | |
| John McKune | Pulmonx Corp | 48 | |
Management Performance
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0839 |
Electromed Leadership Team
Elected by the shareholders, the Electromed's board of directors comprises two types of representatives: Electromed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Electromed. The board's role is to monitor Electromed's management team and ensure that shareholders' interests are well served. Electromed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Electromed's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Amy Yanta, Quality Affairs | ||
| Kathleen Skarvan, CEO and President and Director | ||
| Brad Nagel, Chief Officer | ||
| Diane Kaufman, Vice Resources | ||
| William George, Secretary | ||
| Christopher Holland, Chief Officer | ||
| James Cunniff, Director President | ||
| Bradley Nagel, Chief Officer |
Electromed Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Electromed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0839 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 224.48 M | ||||
| Shares Outstanding | 8.46 M | ||||
| Shares Owned By Insiders | 27.70 % | ||||
| Shares Owned By Institutions | 36.06 % | ||||
| Number Of Shares Shorted | 145.28 K | ||||
| Price To Earning | 23.66 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Electromed is a strong investment it is important to analyze Electromed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Electromed's future performance. For an informed investment choice regarding Electromed Stock, refer to the following important reports:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Electromed. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Electromed Stock refer to our How to Trade Electromed Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Electromed. If investors know Electromed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Electromed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.809 | Earnings Share 0.72 | Revenue Per Share 6.39 | Quarterly Revenue Growth 0.09 | Return On Assets 0.0839 |
The market value of Electromed is measured differently than its book value, which is the value of Electromed that is recorded on the company's balance sheet. Investors also form their own opinion of Electromed's value that differs from its market value or its book value, called intrinsic value, which is Electromed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Electromed's market value can be influenced by many factors that don't directly affect Electromed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Electromed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Electromed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Electromed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.